Metropolis Healthcare Q3 FY25 results: Revenue Up 9.2% YoY to Rs 29,991.31 lakhs, net profit soars 2.6% YoY

In December 2024, the company announced the acquisition of Core Diagnostics Private Limited, a leading diagnostic service provider in India, for ₹24,683 lakhs. This acquisition is expected to enhance the company’s offerings and strengthen its presence in the healthcare sector.

Metropolis Healthcare Limited, a leading provider of diagnostic and pathology services, has announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024. The company’s third quarter of FY 2024-25 performance showed steady growth despite challenging market conditions.

Stand-Alone Performance Highlights

Advertisement

For the quarter ended December 31, 2024, Metropolis Healthcare reported total income of ₹29,991.31 lakhs, up from ₹27,459.72 lakhs during the same period last year. The nine-month period ended December 31, 2024, saw total income of ₹91,404.11 lakhs, a significant increase compared to ₹82,113.64 lakhs during the previous year.

The company’s revenue from Q3 FY 2024-25 operations was ₹29,688.08 lakhs, driven by strong performance across various diagnostic services. Other income stood at ₹303.23 lakhs for the quarter.

Metropolis reported a profit before tax (PBT) of ₹3,679.96 lakhs for Q3, a notable increase over the ₹3,463.13 lakhs reported for Q3 FY 2023-24. For the nine-month period, the profit before tax was ₹13,338.79 lakhs, compared to ₹11,235.46 lakhs for the previous year.

After accounting for taxes, which amounted to ₹939.57 lakhs for the quarter, the company’s profit for the period stood at ₹2,740.39 lakhs, marking a significant increase over the ₹2,669.73 lakhs reported in Q3 FY 2023-24. On a year-to-date basis, Metropolis recorded a profit of ₹10,094.54 lakhs for the period from April 1 to December 31, 2024.

Consolidated Financial Results

The Group, which includes Metropolis Healthcare Limited and its subsidiaries, reported total income of ₹32,532.30 lakhs for Q3 FY 2024-25, a rise from ₹29,342.32 lakhs reported in Q3 FY 2023-24. For the nine-month period ended December 31, 2024, total income stood at ₹99,405.37 lakhs, up from ₹88,328.64 lakhs for the corresponding period of the previous year.

The consolidated revenue from operations for Q3 FY 2024-25 was ₹32,276.74 lakhs, compared to ₹29,111.71 lakhs during Q3 FY 2023-24. The company’s profit before tax for Q3 reached ₹4,233.56 lakhs.

Strategic Developments and Expansion Plans

Metropolis Healthcare continues to grow through strategic initiatives. In December 2024, the company announced the acquisition of Core Diagnostics Private Limited, a leading diagnostic service provider in India, for ₹24,683 lakhs. This acquisition is expected to enhance the company’s offerings and strengthen its presence in the healthcare sector.

Additionally, the company has been actively expanding its workforce through its Restricted Stock Unit (RSU) plans, with 65,700, 58,000, and 22,500 RSUs granted in May, June, and November 2024, respectively.

The company remains confident about maintaining its growth trajectory. With the acquisition of Core Diagnostics, Metropolis is well-positioned to tap into new opportunities in the diagnostic services market. Moreover, the company’s focus on expanding its service offerings and improving operational efficiencies is expected to drive further growth in the coming quarters.

Metropolis Healthcare Limited’s strong financial results for Q3 and the nine-month period of FY 2024-25 reflect the resilience and robust operational strategy of the company. As it continues to innovate and expand its market presence, Metropolis remains a key player in India’s diagnostic services industry, poised for further success in the years ahead.